{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:38:10Z","timestamp":1774931890844,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,1,9]],"date-time":"2015-01-09T00:00:00Z","timestamp":1420761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1245\/s10434-015-4371-0","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T17:12:48Z","timestamp":1420737168000},"page":"2881-2887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Preoperative Carboplatin\u2013Paclitaxel\u2013Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study"],"prefix":"10.1245","volume":"22","author":[{"given":"Valentina","family":"Guarneri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Vittoria","family":"Dieci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Bisagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Boni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Cagossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarita","family":"Pecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PierFranco","family":"Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,9]]},"reference":[{"key":"4371_CR1","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334.","journal-title":"Clin Cancer Res."},{"key":"4371_CR2","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s40265-013-0091-6","volume":"73","author":"V Guarneri","year":"2013","unstructured":"Guarneri V, Dieci MV, Conte P. Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs. 2013;73:1257\u201365.","journal-title":"Drugs."},{"key":"4371_CR3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","volume":"19","author":"M Bonotto","year":"2014","unstructured":"Bonotto M, Gerratana L, Poletto E, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014;19:608\u201315.","journal-title":"Oncologist."},{"key":"4371_CR4","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMp1205737","volume":"366","author":"TM Prowell","year":"2012","unstructured":"Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med. 2012;366:2438\u201341.","journal-title":"N Engl J Med."},{"key":"4371_CR5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet.\u00a02014;384:164\u201372.","journal-title":"Lancet."},{"key":"4371_CR6","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275\u201381.","journal-title":"J Clin Oncol."},{"key":"4371_CR7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/annonc\/mdp062","volume":"20","author":"BK Linderholm","year":"2009","unstructured":"Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 2009;20:1639\u201346.","journal-title":"Ann Oncol."},{"key":"4371_CR8","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","volume":"24","author":"DW Miles","year":"2013","unstructured":"Miles DW, Di\u00e9ras V, Cort\u00e9s\u00a0J, Duenne AA, Yi J, O\u2019Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol. 2013;24:2773\u201380.","journal-title":"Ann Oncol."},{"key":"4371_CR9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/annonc\/mdn669","volume":"20","author":"J Fasano","year":"2009","unstructured":"Fasano J, Muggia F. Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. Ann Oncol. 2009;20:609\u201314.","journal-title":"Ann Oncol."},{"key":"4371_CR10","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A. Hallmarks of \u201cBRCAness\u201d in sporadic cancers. Nat Rev Cancer. 2004;4:814\u20139.","journal-title":"Nat Rev Cancer."},{"key":"4371_CR11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","volume":"28","author":"T Byrski","year":"2010","unstructured":"Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375\u20139.","journal-title":"J Clin Oncol."},{"key":"4371_CR12","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","volume":"28","author":"DP Silver","year":"2010","unstructured":"Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145\u201353.","journal-title":"J Clin Oncol."},{"key":"4371_CR13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10549-012-2100-y","volume":"136","author":"E Alba","year":"2012","unstructured":"Alba E, Chacon JI, Lluch A, et al. A randomized phase II trial of platinum salts in basal like breast cancer patients in the neoadjuvant setting. Results from the GEICAM\/2006-03, multicenter study. Breast Cancer Res Treat. 2012;136:487\u201393.","journal-title":"Breast Cancer Res Treat."},{"key":"4371_CR14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","volume":"15","author":"G Minckwitz Von","year":"2014","unstructured":"Von Minckwitz G, Schneeweiss A, Loibl S, et al. neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15:747\u201356.","journal-title":"Lancet Oncol."},{"key":"4371_CR15","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1093\/annonc\/mdt361","volume":"24","author":"B Gerber","year":"2013","unstructured":"Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline\u2013taxane\u2013based chemotherapy in 678 triple-negative primary breast cancers; results from the Geparquinto Study (GBG 44). Ann Oncol. 2013;24:2978\u201384.","journal-title":"Ann Oncol."},{"key":"4371_CR16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa1111097","volume":"366","author":"HD Bear","year":"2012","unstructured":"Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366:310\u201320.","journal-title":"N Engl J Med."},{"key":"4371_CR17","doi-asserted-by":"crossref","unstructured":"Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. In press.","DOI":"10.1200\/JCO.2014.57.0572"},{"key":"4371_CR18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","volume":"14","author":"D Cameron","year":"2013","unstructured":"Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14:933\u201342.","journal-title":"Lancet Oncol."},{"key":"4371_CR19","doi-asserted-by":"crossref","unstructured":"Miller K, O\u2019Neill AM, Dang CT, et al. Bevacizumab in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol. 2014;32(Suppl 15s):abstr 500.","DOI":"10.1200\/jco.2014.32.15_suppl.500"},{"key":"4371_CR20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","volume":"15","author":"S Pignata","year":"2014","unstructured":"Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3\u00a0weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15:396\u2013405.","journal-title":"Lancet Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-015-4371-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-015-4371-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-015-4371-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T12:21:15Z","timestamp":1566217275000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-015-4371-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["4371"],"URL":"https:\/\/doi.org\/10.1245\/s10434-015-4371-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,9]]}}}